About (HAOH) Shanghai Haohai Biological Technology Co. Ltd.

Company Background

Shanghai Haohai Biological Technology Co., Ltd., symbol HAOH (TRADU:HAOH), is a leading Chinese biotechnology company focused on the research, development, production, and commercialization of biomedical materials and regenerative medicine products. Founded in 2007 and headquartered in Shanghai, China, the company specializes in high-performance biomaterials used in ophthalmology, orthopedics, medical aesthetics, and wound care. Haohai’s core expertise lies in hyaluronic acid-based products, collagen technologies, and other advanced biopolymers that support tissue repair and regeneration. With a commitment to innovation and patient well-being, Haohai Biological aims to advance medical technology and improve clinical outcomes through science-driven solutions.

Market Position

Shanghai Haohai Biological holds a strong position in China’s biomedical materials and regenerative medicine markets. The company is one of the largest producers of hyaluronic acid (HA) in China, serving both medical and cosmetic applications. Its products are widely used by hospitals, clinics, and consumers for ophthalmic surgery, joint therapy, and aesthetic treatments. Haohai has established an extensive domestic sales network and continues to expand internationally through strategic partnerships and regulatory approvals in global markets. By maintaining a vertically integrated business model—from R&D to manufacturing and distribution—the company ensures high quality, cost efficiency, and innovation across its product lines. Its emphasis on clinical validation and international certifications reinforces its credibility and competitiveness in the global biomedical field.

Key Financial and Industry Highlights

Haohai Biological demonstrates consistent financial performance driven by growing demand in medical aesthetics, orthopedic therapy, and advanced wound care. The company benefits from strong margins due to its proprietary technologies and high-value product portfolio. Continuous investment in R&D supports the development of next-generation biopolymers, combination products, and drug-delivery systems. Its recent expansions in regenerative medicine and aesthetic injectables align with global trends toward minimally invasive treatments and longevity-focused healthcare. Haohai also places emphasis on sustainability and quality assurance through its GMP-compliant production facilities and international partnerships.

As the global healthcare and medical aesthetics markets continue to expand, Shanghai Haohai Biological Technology Co., Ltd. is well-positioned to leverage its scientific expertise, innovation-driven culture, and strong brand reputation. With a focus on advanced biomaterials, regenerative therapies, and international growth, the company stands as a key player in the evolution of modern biomedicine and a leading representative of China’s biotechnology excellence on the world stage.